We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck and Co Inc | NYSE:MRK | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.72 | -0.56% | 128.50 | 129.93 | 127.80 | 129.43 | 5,895,709 | 00:55:07 |
From May 2019 to May 2024
By Kimberly Chin
Merck & Co. (MRK) said that an advanced trial of its cancer treatment Keytruda met one of its primary endpoints showing significant improvement in patients who used the drug in conjunction with chemotherapy.
The study offered first-line treatment of patients with extensive-stage, small-cell lung cancer. The company said the trial's results show that the combination had a significant improvement on patients compared with chemotherapy alone.
However, Merck said it didn't meet its other primary endpoint for a patient's overall survival, deeming results had little to no "statistical significance."
Keytruda is an anti-PD-1 therapy that helps increase the body's immune system so that it can detect and fight tumor cells. Merck is testing the treatment across multiple settings and stages of lung cancer.
Shares of Merck were off slightly by 0.7% at $90.99 in after-hours trading.
Write to Kimberly Chin at kimberly.chin@wsj.com
(END) Dow Jones Newswires
January 06, 2020 16:53 ET (21:53 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck Chart |
1 Month Merck Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
